Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07227818 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Name: Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia — clinical trial record (NCT07227818)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorNeurocrine Biosciences

Started2025-12-16

View on ClinicalTrials.gov ↗

Amendment history

2026-09-26

Trial sites expanded: 20 → 25 locations

2026-06-04

Study Status, Contacts/Locations v3

Study sites18→20

2026-05-13

Study Status, Contacts/Locations v2

Study sites17→18

2026-04-10

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-12→confirmed 2025-12-16

Study sites0→17

2025-11-11

Original filing

Neurocrine Biosciences

25 trials monitored

See 1 trial at risk

Schizophrenia

675 trials monitored

See 32 trials at risk

The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

Trial Details

NCT Number	NCT07227818
Lead Sponsor	Neurocrine Biosciences
Conditions	Schizophrenia
Enrollment	560 participants
Start Date	2025-12-16
Primary Completion	2029-07 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-25